Cemiplimab versus historical systemic treatments for locally advanced or metastatic cutaneous squamous cell carcinomas: Results from the French study TOSCA.

Fiche publication

Date publication

mars 2026

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr GRANEL-BROCARD Florence , Dr NARDIN Charlée

Tous les auteurs :
Robert C, Gérard E, Lanoy E, Quéreux G, Bernard P, Viguier M, Grange F, Meyer N, Dinulescu M, Legoupil D, Neidhardt EM, Saiag P, Trabelsi S, Célérier P, Nardin C, Maubec E, Duval-Modeste AB, Hainaut E, Darras S, Maillard H, Guegan S, Arnault JP, Stoebner PE, LE Corre Y, Peuvrel L, Bonniaud B, Herrscher H, Granel-Brocard F, Vataire AL, Tabellion A, Lebbé C, Mortier L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41806521

Résumé

Cemiplimab an anti-programmed cell death receptor-1 antibody, was approved by the FDA and EMA for patients with locally advanced cutaneous squamous cell carcinoma (laCSCC) ineligible for curative surgery/radiotherapy or with metastatic (m) CSCC. TOSCA study evaluated the real-world effectiveness and safety of cemiplimab compared to historical systemic therapies (HSTs).